Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price

Rhea-AI Filing Summary

Zura Bio Ltd reported that officer Kiran Nistala received an option grant for 340,900 Employee Share Options to buy Class A Ordinary Shares at an exercise price of $6.03 per share. These options expire on April 1, 2036 and represent compensation rather than a market purchase.

According to the vesting terms, one fourth of the options will vest on April 1, 2027, with one twelfth of the remaining options vesting in equal quarterly installments thereafter, as long as Nistala continues in service. After this grant, Nistala holds 340,900 derivative securities directly related to this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nistala Kiran

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Employee Share Option (Right to Buy)	340,900	$0.00	--

Holdings After Transaction: Employee Share Option (Right to Buy) — 340,900 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 340,900 options Exercise price: $6.03 per share Underlying shares: 340,900 shares +3 more

6 metrics

Option grant size 340,900 options Employee Share Option award to Kiran Nistala

Exercise price $6.03 per share Strike price for Employee Share Option grant

Underlying shares 340,900 shares Class A Ordinary Shares underlying the options

Shares after transaction 340,900 derivative securities Total options held by Nistala following grant

Expiration date April 1, 2036 Option award expiration

Initial vesting date April 1, 2027 Date when one fourth of options vest

Key Terms

Employee Share Option (Right to Buy), Class A Ordinary Shares, Grant, award, or other acquisition, vesting, +1 more

5 terms

Employee Share Option (Right to Buy) financial

"security_title: Employee Share Option (Right to Buy)"

Class A Ordinary Shares financial

"underlying_security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"shares subject to the option award shall vest on April 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount: 1, derivative securities from this option award"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nistala Kiran

(Last) (First) (Middle)

C/O ZURA BIO LTD

1489 WEST WARM SPRINGS ROAD, #110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Option (Right to Buy)	$6.03	04/01/2026		A		340,900		(1)	04/01/2036	Class A Ordinary Shares	340,900	$0	340,900	D

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Zura Bio (ZURA) insider Kiran Nistala report on this Form 4?

Kiran Nistala reported receiving an option grant for 340,900 Employee Share Options. These options allow the purchase of Class A Ordinary Shares at a fixed price as part of compensation, rather than reflecting an open-market stock trade.

How many Zura Bio (ZURA) shares are covered by Kiran Nistala’s option grant?

The option grant covers 340,900 underlying Class A Ordinary Shares. Each option represents the right to buy one share, giving Nistala potential future equity exposure if the options vest and are exercised according to the stated schedule.

What is the exercise price and expiration date of Kiran Nistala’s Zura Bio options?

The options have a fixed exercise price of $6.03 per share and expire on April 1, 2036. This means Nistala can buy shares at $6.03, if vested, any time before the expiration date, subject to the vesting conditions.

How do the Zura Bio (ZURA) options granted to Kiran Nistala vest over time?

One fourth of the options will vest on April 1, 2027. The remaining three fourths then vest in equal quarterly installments, each covering one twelfth of the remainder, contingent on Nistala’s continuous service through each vesting date.

Is Kiran Nistala’s Form 4 transaction a market purchase or sale of Zura Bio stock?

The Form 4 shows an option grant classified as a grant, award, or other acquisition, not a market trade. Nistala did not buy or sell shares in the open market; instead, they received stock options as part of their compensation package.

How many derivative securities does Kiran Nistala hold in Zura Bio after this grant?

After the reported transaction, Nistala holds 340,900 derivative securities from this option award. These represent rights to acquire Class A Ordinary Shares if vesting conditions are met and the options are exercised before the 2036 expiration date.